Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur StandardtherapieRandomized controlled study to evaluate the efficacy of Adalimumab in patients with different forms of refractory Uveitis

Phase 1

• Conditions: Adalimumab in treatment of refractory uveitis; MedDRA version: 8.1Level: LLTClassification code 10046851Term: Uveitis

• Registration Number: EUCTR2006-001732-53-DE
• Lead Sponsor: niversity Hospital of Heidelberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-06-13
• Study Completion: 2013-01-08
• Last Update Posted: 24 August 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified